Director VALOR IV PHARMA HOLDINGS LLC Plans $26.6M Stock Sale
HRMY sits 51% above its 52-week low of $25.52.
Summary
Director VALOR IV PHARMA HOLDINGS LLC filed a Form 144 to sell $26.6 million in Harmony Biosciences stock, continuing a trend of insider sales amid strong Q2 results and recent CFO turnover.
Key Events · Ownership and Investor Activity · HRMY
-
Director Plans $26.6M Sale
VALOR IV PHARMA HOLDINGS LLC, a Director, filed a Form 144 to sell 700,883 shares worth approximately $26.6 million, with the sale expected on or around August 7, 2026.
-
Recent Sales Total $4.3M
The same filer sold 116,490 shares in the past three months for gross proceeds of $4.3 million, indicating ongoing liquidation.
-
Insider Selling Trend
This filing adds to a pattern of insider sales, including multiple Form 144s by the former CFO in June 2026, and follows the recent CFO resignation on July 16, 2026.
-
Strong Q2 Results Backdrop
The planned sale comes just days after Harmony reported record Q2 2026 revenue of $261.3 million and reaffirmed $1 billion+ full-year guidance, potentially providing a favorable exit window.
Analysis · HRMY · Life Sciences
A Director intends to sell 700,883 shares valued at roughly $26.6 million, adding to the $4.3 million in sales already executed over the past three months. Although the filer is a Director rather than a C-suite executive, the proposed transaction is sizable relative to the company's market cap and extends a pattern of insider selling that includes recent CFO departures. This could signal reduced confidence or portfolio rebalancing by a long-term holder.
At the time of this filing, HRMY was trading at $38.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $25.52 to $40.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.